Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Trial Profile

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Conestat alfa (Primary)
  • Indications Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; COVID-19 pneumonia
  • Focus Therapeutic Use
  • Acronyms PROTECT-COVID-19

    • Most Recent Events

    • 01 Nov 2021 Status changed from active, no longer recruiting to discontinued.
    • 13 Sep 2021 According to a Pharming Group NV media release, the company will analyze the full results as it will design future clinical trials with RUCONEST for the treatment of COVID-19, as well as other serious conditions.
    • 13 Sep 2021 According to a Pharming Group NV media release, study has been concluded and results will be published in peer-review medical journals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.